Clinical Neuroscience of Addiction: Similarities and Differences Between Alcohol and Other Drugs
- 28 September 2015
- journal article
- review article
- Published by Wiley in Alcohol, Clinical and Experimental Research
- Vol. 39 (11) , 2073-2084
Abstract
Background: Existing pharmacological treatments for alcohol use disorder (AUD) and other substance use disorders (SUDs) have demonstrated only modest efficacy. Although the field has recently emphasized testing and developing new compounds to treatSUDs, there are numerous challenges inherent to the development of novel medications, and this is particularly true forSUDs. Thus, research to date has tended toward the “repurposing” approach, in which medications developed to treat other mental or physical conditions are tested asSUDtreatments. Often, potential treatments are examined across numerous drugs of abuse. Several repurposed medications have shown promise in treating a specificSUD, but few have shown efficacy across multipleSUDs. Examining similarities and differences betweenAUDand otherSUDs may shed light on these findings and offer directions for future research.Methods: This qualitative review discusses similarities and differences in neural circuitry and molecular mechanism(s) across alcohol and other substances of abuse, and examines studies of pharmacotherapies forAUDand otherSUDs.Results: Substances of abuse share numerous molecular targets and involve much of the same neural circuitry, yet compounds tested because they putatively target common mechanisms have rarely indicated therapeutic promise for multipleSUDs.Conclusions: The lack of treatment efficacy acrossSUDs may be partially explained by limitations inherent in studying substance users, who comprise a highly heterogeneous population. Alternatively, medications may fail to show efficacy across multipleSUDs due to the fact that the differences between drug mechanisms are more important than their commonalities in terms of influencing treatment response. We suggest that exploring these differences could support novel treatment development, aid in identifying existing medications that may hold promise as treatments for specificSUDs, and ultimately advance translational research efforts.Keywords
Funding Information
- National Science Foundation (DGE 1144083)
This publication has 161 references indexed in Scilit:
- Assessing Cue-Induced Brain Response as a Function of Abstinence Duration in Heroin-Dependent Individuals: An Event-Related fMRI StudyPLOS ONE, 2013
- Varenicline decreases alcohol consumption in heavy-drinking smokersPsychopharmacology, 2012
- Immune system inflammation in cocaine dependent individuals: implications for medications developmentHuman Psychopharmacology: Clinical and Experimental, 2012
- A Proof-of-Concept Randomized Controlled Study of Gabapentin: Effects on Cannabis Use, Withdrawal and Executive Function Deficits in Cannabis-Dependent AdultsNeuropsychopharmacology, 2012
- Dysfunction of the prefrontal cortex in addiction: neuroimaging findings and clinical implicationsNature Reviews Neuroscience, 2011
- Results of an initial clinical trial of varenicline for the treatment of cocaine dependenceDrug and Alcohol Dependence, 2011
- The “Toll” of Opioid-Induced Glial Activation: Improving the Clinical Efficacy of Opioids by Targeting GliaTrends in Pharmacological Sciences, 2009
- Neurocircuitry of AddictionNeuropsychopharmacology, 2009
- Varenicline Reduces Alcohol Self-Administration in Heavy-Drinking SmokersBiological Psychiatry, 2009
- Increased MCP-1 and microglia in various regions of the human alcoholic brainExperimental Neurology, 2008